药物评估：硫氧还蛋白抑制剂PX - 12在癌症治疗中的应用
Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.
作者信息
Galmarini Carlos M
机构信息
Université Claude Bernard Lyon 1, EA3737 Pathologie des Cellules Lymphoides, UFR de Médecin Lyon-Sud, Centre Hospitalier Lyon-Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Bénite, France.
出版信息
Curr Opin Investig Drugs. 2006 Dec;7(12):1108-15.
PMID:17209529
Abstract
Biomira Inc, following its acquisition of ProlX Pharmaceutical Corp, is developing PX-12, an inhibitor of thioredoxin, for the potential treatment of cancer. PX-12 has completed phase I clinical trials.
摘要
Biomira公司在收购ProlX制药公司后，正在研发PX-12（一种硫氧还蛋白抑制剂）用于癌症的潜在治疗。PX-12已完成I期临床试验。
Zotero 插件